Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Feb;71(2):331–336. doi: 10.1038/bjc.1995.66

A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma.

A Ravaud 1, E Legrand 1, M M Delaunay 1, E Bussières 1, V Coulon 1, L Cany 1, S Huet 1, D Verdier 1, M Kind 1, F Chomy 1, et al.
PMCID: PMC2033579  PMID: 7530984

Abstract

The aim of the protocol was to evaluate the side-effects induced by repeated tumour-infiltrating lymphocyte (TIL) infusions in patients with metastatic melanoma (MM). Patients were to receive four TIL infusions at given intervals: every 3 weeks (two patients), every 2 weeks (3 patients) and weekly (4 patients). All patients were evaluated and received a total of 34 TIL infusions. The total number of TILs administered varied from 0.65 to 2.34 x 10(11) cells. TIL phenotypes were predominantly CD8+ (two patients), CD4+ (4 patients), CD4+ then CD8+ (two patients) or CD56+ (two patient). Autocytotoxicity was only observed for one culture. Six patients presented at least one WHO grade 3 side-effect: hypotension (5 patients), dyspnoea (two patients), fever (one patient), fatigue (one patient), chills (two patients), diarrhoea (one patient), agitation (one patient), locoregional pain (two patients). Hypotension was constantly seen in patients who were given TILs every week. Two cases of minor pericarditis were recorded. No objective response to treatment was observed; 1 stable disease occurred in one patient and progression in eight. However, five patients presented a partial response on a tumour site for 1-4 months. Three patients presented signs of inflammation or softening at one tumour site. Plasma tumour necrosis factor alpha (TNF-alpha) levels were increased 1.2- to 22-fold after TIL infusion. TILs could be produced in sufficient quantity to perform this study, so repetitive infusions of TIL became possible on a weekly basis. However, no objective response was observed even when TIL infusions were performed weekly. An increase in circulating TNF-alpha was noted after TIL infusion.

Full text

PDF
331

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beutler B. A., Milsark I. W., Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol. 1985 Dec;135(6):3972–3977. [PubMed] [Google Scholar]
  2. Bukowski R. M., Sharfman W., Murthy S., Rayman P., Tubbs R., Alexander J., Budd G. T., Sergi J. S., Bauer L., Gibson V. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res. 1991 Aug 15;51(16):4199–4205. [PubMed] [Google Scholar]
  3. Cole D. J., Taubenberger J. K., Pockaj B. A., Yannelli J. R., Carter C., Carrasquillo J., Leitman S., Steinberg S. M., Rosenberg S. A., Yang Y. C. Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes. Cancer Immunol Immunother. 1994 May;38(5):299–303. doi: 10.1007/BF01525507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dorval T., Mathiot C., Brandely M., Escande M. C., Fridman W. H., Pouillart P. Lack of effect of tumour infiltrating lymphocytes in patients with metastatic melanoma who failed to respond to interleukin 2. Eur J Cancer. 1992;28(2-3):615–616. doi: 10.1016/s0959-8049(05)80107-8. [DOI] [PubMed] [Google Scholar]
  5. Fisher B., Packard B. S., Read E. J., Carrasquillo J. A., Carter C. S., Topalian S. L., Yang J. C., Yolles P., Larson S. M., Rosenberg S. A. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol. 1989 Feb;7(2):250–261. doi: 10.1200/JCO.1989.7.2.250. [DOI] [PubMed] [Google Scholar]
  6. Fossati G., Anichini A., Squarcina P., Mazzocchi A., Parmiani G. Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma. Int J Cancer. 1988 Aug 15;42(2):239–245. doi: 10.1002/ijc.2910420216. [DOI] [PubMed] [Google Scholar]
  7. Hom S. S., Schwartzentruber D. J., Rosenberg S. A., Topalian S. L. Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J Immunother Emphasis Tumor Immunol. 1993 Jan;13(1):18–30. doi: 10.1097/00002371-199301000-00003. [DOI] [PubMed] [Google Scholar]
  8. Itoh K., Platsoucas C. D., Balch C. M. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med. 1988 Oct 1;168(4):1419–1441. doi: 10.1084/jem.168.4.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kirkwood J. M., Ernstoff M. Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma. Semin Oncol. 1986 Sep;13(3 Suppl 2):48–56. [PubMed] [Google Scholar]
  10. Kradin R. L., Boyle L. A., Preffer F. I., Callahan R. J., Barlai-Kovach M., Strauss H. W., Dubinett S., Kurnick J. T. Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother. 1987;24(1):76–85. doi: 10.1007/BF00199837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kradin R. L., Kurnick J. T., Lazarus D. S., Preffer F. I., Dubinett S. M., Pinto C. E., Gifford J., Davidson E., Grove B., Callahan R. J. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet. 1989 Mar 18;1(8638):577–580. doi: 10.1016/s0140-6736(89)91609-7. [DOI] [PubMed] [Google Scholar]
  12. Marincola F. M., Balkissoon J., Schwartzentruber D. J., Hom S. S., Concepcion R., Marcus S. G., Yannelli J., Topalian S. L., Parkinson D. R., Rosenberg S. A. Hemodynamic effects of the administration of tumor-infiltrating lymphocytes to cancer patients. J Immunother Emphasis Tumor Immunol. 1993 May 4;13(4):282–288. doi: 10.1097/00002371-199305000-00008. [DOI] [PubMed] [Google Scholar]
  13. Muul L. M., Spiess P. J., Director E. P., Rosenberg S. A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol. 1987 Feb 1;138(3):989–995. [PubMed] [Google Scholar]
  14. Ravaud A., Lakdja F., Delaunay M., Coulon V., Regaudie J. J., Bui N. B. Cardiomyopathy after acute myocardial infarction after therapy with interleukin-2 and tumour infiltrating lymphocytes. Eur J Cancer. 1992;28A(10):1772–1772. doi: 10.1016/0959-8049(92)90094-i. [DOI] [PubMed] [Google Scholar]
  15. Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989 Oct;210(4):474–485. doi: 10.1097/00000658-198910000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rosenberg S. A., Packard B. S., Aebersold P. M., Solomon D., Topalian S. L., Toy S. T., Simon P., Lotze M. T., Yang J. C., Seipp C. A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–1680. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  17. Schwartzentruber D. J., Topalian S. L., Mancini M., Rosenberg S. A. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol. 1991 May 15;146(10):3674–3681. [PubMed] [Google Scholar]
  18. Spiess P. J., Yang J. C., Rosenberg S. A. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst. 1987 Nov;79(5):1067–1075. [PubMed] [Google Scholar]
  19. Topalian S. L., Muul L. M., Solomon D., Rosenberg S. A. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987 Aug 24;102(1):127–141. doi: 10.1016/s0022-1759(87)80018-2. [DOI] [PubMed] [Google Scholar]
  20. Topalian S. L., Solomon D., Avis F. P., Chang A. E., Freerksen D. L., Linehan W. M., Lotze M. T., Robertson C. N., Seipp C. A., Simon P. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol. 1988 May;6(5):839–853. doi: 10.1200/JCO.1988.6.5.839. [DOI] [PubMed] [Google Scholar]
  21. Topalian S. L., Solomon D., Rosenberg S. A. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989 May 15;142(10):3714–3725. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES